1 / 9

Innovative Cancer Therapies: Methylnaltrexone, PSMA Vaccines, and HIV Entry Inhibitors Overview

This overview discusses the discontinuation of Methylnaltrexone in cancer treatment and highlights ongoing advancements in prostate cancer vaccines through a joint venture with Cytogen. It covers Phase 1 clinical trials for a new vaccine targeting malignant melanoma, as well as promising results from Phase II trials of PRO 542, demonstrating significant reductions in viral load for HIV treatment. Additionally, we analyze the financial outlook for Provax amidst its ongoing research efforts, projecting upcoming financing opportunities.

aldis
Télécharger la présentation

Innovative Cancer Therapies: Methylnaltrexone, PSMA Vaccines, and HIV Entry Inhibitors Overview

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Methylnaltrexone

  2. Cancer Vaccines GMK Malignant Melanoma- discontinued PSMA - Joint Venture with CytogenPhase 1 prostate cancer vaccine Preclin - antibody and viral vector

  3. HIV Entry Inhibitors • PRO 542 • PII(single dose) (n=12) - 60-80% reduction in viral load • PII(multi-dose) - ongoing Preclinical: PRO 140, Provax

  4. Cash  Burn Rate = Quarters Left (22.5 - 2.6)  7.4 ≈ 2.6 Expect Upcoming Financing!

More Related